PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DUR...

por Naylor, G. U., Mant, S., Bedford, C., Turner, D., Furtado, M., Lewis, D.
Publicado 2022

Retinoblastoma protein regulates the crosstalk between autophagy and apoptosis, and favors glioblastoma resistance to etoposide

por Biasoli, D, Kahn, S A, Cornélio, T A, Furtado, M, Campanati, L, Chneiweiss, H, Moura-Neto, V, Borges, H L
Publicado 2013